BlossomHill Therapeutics
Last verified 2026-05-17. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $257.0Mattributed |
|---|---|
| Latest round | series-b, $84.0M, 2025-12-01attributed |
| Founded | 2020 |
| Headquarters | San Diego, USA |
| Industry | bio |
| Stage | series-b+ |
| Website | blossomhilltx.com |
Discovers small-molecule cancer drugs including BH-30643, a mutant-selective OMNI-EGFR inhibitor, and BH-30236, a CLK inhibitor for relapsed AML and MDS. Built for patients with EGFR/HER2-mutant NSCLC and high-risk hematologic cancers. Co-founded by J. Jean Cui, the chemist behind crizotinib, lorlatinib and repotrectinib, with $257M raised to date.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-12-01 | series-b | $84.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $84.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $257.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | blossomhilltx.com, read 2026-05-17 |
| Description | self-reported | blossomhilltx.com, read 2026-05-17 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.